

7 Supplementary data

Table 7-1. Expression of *RASSF1A* and *RASSF1C* in the different human tissues

	<i>RASSF1A</i>		<i>RASSF1C</i>	
	Average	Standard deviation	Average	Standard deviation
Heart	56.92%	7.68%	42.45%	5.16%
Brain	3.29%	0.52%	7.11%	1.01%
Placenta	26.42%	13.62%	26.04%	0.00%
Lung	43.75%	5.16%	58.72%	8.65%
Liver	67.66%	0.00%	41.15%	8.12%
Sk. Muscle	1.30%	0.98%	2.58%	0.72%
Kidney	8.98%	2.02%	30.13%	5.91%
Pancreas	100.00%	24.00%	100.00%	1.10%

Table 7-2. Analysis of the *RASSF1A* and *RASSF1C* expressions in the different cell lines

	<i>RASSF1A</i>		<i>RASSF1C</i>	
	Average	Standard deviation	Average	Standard deviation
PBMC	197.28%	6.79%	146.74%	7.61%
HeLa	115.93%	3.12%	67.12%	4.07%
HF	100.00%	2.74%	100.00%	4.95%
Mammary gland	8.16%	1.54%	7.88%	3.93%
pre-stasis	15.81%	1.86%	155.42%	52.08%
stasis	6.65%	2.03%	904.25%	1431.44%
post-stasis	3.71%	1.95%	260.02%	361.78%
T47D	0.21%	0.20%	110.57%	5.92%
T47D Aza	2.54%	0.94%	91.78%	0.40%
ZR75-1	0.72%	0.63%	336.61%	29.97%
ZR75-1 Aza	3.22%	0.34%	277.66%	36.46%
MCF7	0.00%	0.00%	99.19%	11.49%
MCF7 Aza	3.42%	0.47%	190.25%	18.16%

Table 7-3. Analysis of the *RASSF1A* and *RASSF1C* expressions in HMEC-184 and HMEC-48R

	<i>RASSF1A</i>		<i>RASSF1C</i>	
	Average	Standard deviation	Average	Standard deviation
184 p3	16.85%	0.81%	207.22%	71.97%
184 p6	14.83%	1.29%	174.81%	11.17%
184 stasis	8.89%	0.79%	2557.12%	489.56%
184 p7	2.88%	0.64%	187.42%	28.19%
184 p8	2.27%	0.32%	32.44%	10.29%
48R p3	17.47%	1.69%	105.55%	16.87%
48R p4	13.02%	0.82%	195.15%	36.20%
48R stasis	4.93%	0.97%	70.58%	0.31%
48R p6	5.74%	1.10%	207.31%	42.48%
48R p8	3.02%	0.69%	95.81%	11.63%
48R p12	3.01%	0.57%	178.78%	12.28%
48R p16	1.98%	0.79%	83.93%	0.68%

Table 7-4. The *RASSF1A* and *RASSF1C* expressions in HMEC-184 passage13 after 5-Aza-CdR treatment.

	<i>RASSF1A</i>		<i>RASSF1C</i>	
	Average	Standard deviation	Average	Standard deviation
Control	100.00%	0.00%	100.00%	0.00%
Aza treatment	393.00%	32.19%	115.00%	7.81%

Table 7-5. The *p16^{INK4}* expression pattern in HMEC-141 and HMEC-219.

	Average	Standard deviation
HeLa	100.00%	0.00%
HF	3.81%	0.08%
HMEC-141 p2	26.10%	6.36%
HMEC-141stasis	87.80%	17.41%
HMEC-219 p7	0.52%	0.20%
HMEC-219 p11	0.40%	0.17%
HMEC-219 p14	0.38%	0.09%

Table 7-6. Frequency of acetylated histone H3 in the *RASSF1A* and *RASSF1C* promoters.

	<i>RASSF1A</i>				<i>RASSF1C</i>	
	A2		A1		C	
	Average	Standard deviation	Average	Standard deviation	Average	Standard deviation
HeLa	1126.03%	460.81%	778.00%	115.66%	329.38%	140.57%
HMEC p6	281.34%	27.51%	290.24%	23.86%	285.37%	36.77%
HMEC p12	145.04%	15.50%	121.93%	21.20%	446.18%	91.26%
ZR75-1	38.48%	5.11%	35.35%	3.91%	150.46%	4.39%

Table 7-7. Frequency of trimethylated histone H3 lysine 9 in the *RASSF1A* and *RASSF1C* promoters.

	<i>RASSF1A</i>				<i>RASSF1C</i>	
	A2		A1		C	
	Average	Standard deviation	Average	Standard deviation	Average	Standard deviation
HeLa	5.75%	4.50%	4.97%	4.09%	3.39%	3.50%
HMEC p6	21.19%	1.36%	19.42%	2.08%	10.39%	4.62%
HMEC p12	19.95%	6.44%	42.45%	10.05%	4.40%	3.02%
ZR75-1	1.38%	0.88%	1.71%	1.03%	2.05%	0.62%

Table 7-8. The *Sp1* binding to the *RASSF1A* and *RASSF1C* promoters.

	<i>RASSF1A</i>				<i>RASSF1C</i>	
	A2		A1		C	
	Average	Standard deviation	Average	Standard deviation	Average	Standard deviation
HeLa	3.65%	2.20%	10.32%	3.14%	11.31%	7.39%
HMEC p6	7.70%	1.14%	13.35%	0.30%	13.43%	1.21%
HMEC p12	-0.33%	1.41%	1.78%	0.61%	32.07%	5.59%
ZR75-1	1.27%	0.36%	2.45%	1.49%	21.09%	2.35%